BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this non-interventional, cross-sectional study, BCR::ABL(P210)mRNA was simultaneously measured by dPCR and qPCR in peripheral blood samples collected from patients with CML who underwent tyrosine kinase inhibitor therapy and who achieved at least a complete cytogenetic response from September 2021 to February 2023 at Peking University People's Hospital.